Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

BACKGROUND: Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab, an anti-PD1 monoclonal antibody, with hypofractio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Sahebjam, Solmaz, Forsyth, Peter A, Tran, Nam D, Arrington, John A, Macaulay, Robert, Etame, Arnold B, Walko, Christine M, Boyle, Theresa, Peguero, Edwin N, Jaglal, Michael, Mokhtari, Sepideh, Enderling, Heiko, Raghunand, Natarajan, Gatewood, Tyra, Long, Wendy, Dzierzeski, Jennifer L, Evernden, Brittany, Robinson, Timothy, Wicklund, Melissa C, Kim, Sungjune, Thompson, Zachary J, Chen, Dung-Tsa, Chinnaiyan, Prakash, Yu, Hsiang-Hsuan Michael
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Clinical Investigations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8041351/
https://ncbi.nlm.nih.gov/pubmed/33173935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa260
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki